NeuroPsy InfoHub adună studii și articole verificate editorial despre sănătate mintală și afecțiuni neurologice — pentru pacienți, familii și specialiști.
Disease-modifying Alzheimer's drugs provide hope for some patients, though their efficacy varies. The article emphasizes that dementia care must extend beyond pharmacological interventions to preserve quality of life and human dignity for all affected individuals, regardless of medication response.
Alzheimer's disease is characterized by the accumulation of tau, a toxic protein that damages neurons. As tau spreads throughout the brain to new regions, cognitive decline accelerates and the disease progresses in severity.
This study examined whether plasma levels of ergothioneine and its metabolite hercynine correlate with resistance to cognitive decline in older dementia-free individuals with Alzheimer's amyloid pathology. Higher ergothioneine metabolism (HC:ET ratio) attenuated the relationship between amyloid biomarkers and cognitive decline, suggesting ergothioneine's potential neuroprotective role warrants further investigation.
This systematic review of five studies involving over 1.6 million participants examines how microvascular complications from diabetes—particularly neuropathy and nephropathy—increase dementia risk, with hazard ratios ranging from 1.12-1.26. Poor glycemic control (HbA1c) and its variability independently contribute to cognitive decline, with each 1% increase in HbA1c associated with an 8% increased dementia risk.
This study investigates potential mechanisms linking thyroid dysfunction (hyper- and hypothyroidism) to Alzheimer's disease risk by measuring serum biomarkers including Aβ42, BDNF, acetylcholinesterase, and calcium in older adults. Results showed elevated Aβ42 and BDNF levels in both thyroid disorder groups compared to controls, with more pronounced elevations in hypothyroid patients, suggesting thyroid dysfunction may influence cognitive decline pathways.
